These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29105802)

  • 1. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
    Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
    Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
    Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM
    J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.
    Gonzales JC; Fink LM; Goodman OB; Symanowski JT; Vogelzang NJ; Ward DC
    Clin Genitourin Cancer; 2011 Sep; 9(1):39-45. PubMed ID: 21723797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).
    Goldkorn A; Tangen C; Plets M; Morrison GJ; Cunha A; Xu T; Pinski JK; Ingles SA; Triche T; Harzstark AL; Kohli M; MacVicar GR; Vaena DA; Crispino AW; McConkey DJ; Lara PN; Hussain MHA; Quinn DI; Vogelzang NJ; Thompson IM; Agarwal N
    Clin Cancer Res; 2021 Apr; 27(7):1967-1973. PubMed ID: 33500355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
    Goldkorn A; Tangen C; Plets M; Bsteh D; Xu T; Pinski JK; Ingles S; Triche TJ; MacVicar GR; Vaena DA; Crispino AW; McConkey DJ; Lara PN; Hussain MHA; Quinn DI; Dorff TB; Lerner SP; Thompson I; Agarwal N
    JAMA Netw Open; 2024 Oct; 7(10):e2437871. PubMed ID: 39374015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer.
    Wong RL; Duong MT; Tangen CM; Agarwal N; Cheng HH; Vogelzang NJ; Hussain M; Thompson IM; Quinn DI; Yu EY
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):486-493. PubMed ID: 32055002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
    Goldkorn A; Ely B; Quinn DI; Tangen CM; Fink LM; Xu T; Twardowski P; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Datar RH; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Thompson IM; Cote RJ; Vogelzang NJ
    J Clin Oncol; 2014 Apr; 32(11):1136-42. PubMed ID: 24616308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
    Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
    Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
    Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
    Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer.
    McDonald AC; Vira M; Shen J; Sanda M; Raman JD; Liao J; Patil D; Taioli E
    Prostate; 2018 May; 78(6):411-418. PubMed ID: 29383739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating microRNAs in plasma before and after radical prostatectomy.
    McDonald AC; Raman JD; Shen J; Liao J; Pandya B; Vira MA
    Urol Oncol; 2019 Nov; 37(11):814.e1-814.e7. PubMed ID: 31421994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
    Jin W; Fei X; Wang X; Chen F; Song Y
    J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
    De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
    Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
    Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
    Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
    Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
    Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.
    Goldkorn A; Ely B; Tangen CM; Tai YC; Xu T; Li H; Twardowski P; Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Vogelzang NJ; Thompson IM; Cote RJ; Quinn DI
    Int J Cancer; 2015 Apr; 136(8):1856-62. PubMed ID: 25219358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.
    Souza MF; Kuasne H; Barros-Filho MC; Cilião HL; Marchi FA; Fuganti PE; Paschoal AR; Rogatto SR; Cólus IMS
    PLoS One; 2017; 12(9):e0184094. PubMed ID: 28910345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer.
    Zhu W; Liu M; Fan Y; Ma F; Xu N; Xu B
    Cancer Med; 2018 Sep; 7(9):4420-4433. PubMed ID: 30099860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
    Cho H; Byun SS; Son NH; Chung JI; Seo WI; Lee CH; Morgan TM; Han KH; Chung JS
    Clin Cancer Res; 2024 May; 30(9):1788-1800. PubMed ID: 38587547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.